ReviewAdvances in therapy2016
Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma.
Review in Advances in therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 2 syntheses or guidelines pooled it, 158 citations in OpenAlex.
- Efficacy of Transarterial Radioembolization and Transarterial Chemoembolization as Downstaging or Bridging Strategies for Hepatocellular Carcinoma Before Liver Transplantation: A Systematic Review and Meta-Analysis.Cardiovascular and interventional radiology · 2026Pooled it
- Pooled it
- Quantitative Contrast-enhanced Ultrasound Evaluation of Hepatocellular Carcinoma Radioembolization.Investigative radiology · 2026Trial
- Microbubble-based Radiosensitization of Hepatocellular Carcinoma: Evaluation of Safety and Efficacy in a Phase II Randomized Trial.Radiology · 2025Trial
- Safety and Efficacy ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Trial
- Predictors of Hepatic Decompensation Post-Y90 Treatment in Hepatocellular Carcinoma: New Insights into Segmental TARE and Post-Treatment Dosimetry.Journal of gastrointestinal cancer · 2026Article
- Transarterial Radioembolization in the Treatment of Hepatocellular Carcinoma and Combination Strategies.Maedica · 2026Review
- Portal vein embolization for arterio-portal shunt closure in hepatocellular carcinoma to facilitate selective internal radiation therapy.World journal of radiology · 2026Article
- Review
- The State of the Art in Combination Locoregional and Systemic Treatment Strategies for Hepatocellular Carcinoma: Recent Advancements and Future Horizons.Current oncology (Toronto, Ont.) · 2026Review
- The evolution of surrogate microspheres in transarterial radioembolization: from SPECT prediction to multimodal AI-guided precision dosimetry.Theranostics · 2026Review
- The Evolving Application of Radiation Segmentectomy for the Treatment of Hepatic Malignancy.Radiology · 2025Review
- Increased Voxel-Based Y90 Radioembolization Dose to Hepatocellular Carcinoma Improves Imaging Response.Cardiovascular and interventional radiology · 2025Article
- Advances and Emerging Techniques in Y-90 Radioembolization for Hepatocellular Carcinoma.Cancers · 2025Review
- Article
- Tumor ablation in children.Pediatric radiology · 2025Review
- Interactions between tumor microenvironment and resistance to transarterial and systemic treatments for HCC.Cancer drug resistance (Alhambra, Calif.) · 2025Review
- The role of radiological interventions in hepatocellular carcinoma before liver transplantation: a surgical perspective.Frontiers in surgery · 2025Review
- Current Treatment Methods in Hepatocellular Carcinoma.Cancers · 2024Review
- Review
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is a common cause of worldwide mortality. Transarterial radioembolization (TARE) with yttrium-90 (Y90), a transcatheter intra-arterial procedure performed by interventional radiology, has become widely utilized in managing HCC.
methodsThe following is a focused review of TARE covering its commercially available products, clinical considerations of treatment, salient clinical trial data establishing its utility, and the current and future roles of TARE in the management of HCC.
resultsTARE is indicated for patients with unresectable, intermediate stage HCC. The two available products are glass and resin microspheres. All patients undergoing TARE must be assessed with a history, physical examination, clinical laboratory tests, imaging, and arteriography with macroaggregated albumin. TARE is safe and effective in the treatment of unresectable HCC, as it has a safer toxicity profile than chemoembolization, longer time-to-progression, greater ability to downsize and/or bridge patients to liver transplant, and utility in tumor complicated by portal vein thrombosis. TARE can also serve as an alternative to ablation and chemotherapy.
conclusionTARE assumes an integral role in the management of unresectable HCC and has been validated by numerous studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.